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Objective. To develop and validate a risk score for detecting cases of undiagnosed diabetes in a resource-constrained country.
Methods. Two population-based studies in Peruvian population aged ≥35 years were used in the analysis: the ENINBSC survey
(𝑛 = 2,472) and the CRONICAS Cohort Study (𝑛 = 2,945). Fasting plasma glucose ≥7.0mmol/L was used to diagnose diabetes
in both studies. Coefficients for risk score were derived from the ENINBSC data and then the performance was validated using
both baseline and follow-up data of the CRONICAS Cohort Study. Results.The prevalence of undiagnosed diabetes was 2.0% in the
ENINBSC survey and 2.9% in the CRONICAS Cohort Study. Predictors of undiagnosed diabetes were age, diabetes in first-degree
relatives, andwaist circumference. Score values ranged from0 to 4, with an optimal cutoff≥2 and had amoderate performancewhen
applied in theCRONICASbaseline data (AUC=0.68; 95%CI: 0.62–0.73; sensitivity 70%; specificity 59%).Whenpredicting incident
cases, the AUC was 0.66 (95% CI: 0.61–0.71), with a sensitivity of 69% and specificity of 59%. Conclusions. A simple nonblood
based risk score based on age, diabetes in first-degree relatives, and waist circumference can be used as a simple screening tool for
undiagnosed and incident cases of diabetes in Peru.
1. Introduction
As of 2014, the worldwide prevalence of type 2 diabetes
mellitus (T2DM) was estimated to be 9% among adults aged
≥18 years with great impact on mortality, particularly in
low- and middle-income countries (LMIC) [1, 2]. Moreover,
globally, approximately 25% to 75% of diabetes cases remain
undiagnosed [3, 4], until further complications, especially at
the macro- and micro-vascular level, manifest clinically. In
Latin America, the proportion of undiagnosed diabetes at the
population level ranged from 33% to 50% [5].
An important strategy to prevent or delay T2DM com-
plications is the early identification of those with undiag-
nosed diabetes; yet, universal screening for diabetes at the
population level is not practical in resource-limited settings.
The American Diabetes Association recommends the use of
glucose test as T2DM screening in people with overweight
and obesity as well as in those with other risk factors [6].
As a result, risk assessment scores have been developed
to address this problem in a simple and inexpensive way.
Most of the available algorithms for diabetes screening have
been developed in Caucasian [7–9] and Asian populations
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[10–13] and very few in other ethnic groups [14, 15]. To date,
one diabetes risk score has been developed and validated
in Latin America so far which was derived from one urban
area in Brazil [16], thus bearing limited generalizability to the
wider region. Furthermore, it is well established that before
adopting existing risk scores as screening tools in different
populations and ethnic groups, their performance needs to
be evaluated, calibrated, or validated in local settings [17].
As the American Diabetes Association, the Peruvian
Ministry ofHealth recommends diabetes screening in general
population with fasting glucose in adults aged 40 to 70 years
with risk factors. However, fasting glucose is not always
available in primary care settings, especially in semiurban and
rural areas. As a result, a major challenge to be overcome in
many countries is the implementation of a simple, fast, and
laboratory-free based screening method.
Consequently, we aimed to develop a simple laboratory-
free risk score to identify people with undiagnosed diabetes
and incident diabetes in Peru, a Latin American country that
spans coastal, Andean, and rainforest settings. In order to do
so, this work benefited from two large-scale population-based
surveys: the first one, representative at the national level, was
used to develop the score, and the second one, a cohort study,
was utilized for external validation.
2. Methods
2.1. Study Design and Participants. Two different population-
based studies were used in this analysis. The National Survey
of Nutritional and Biochemical Indicators for Noncommu-
nicable Diseases (ENINBSC in Spanish), conducted by the
Peruvian National Institute of Health [18], was used to
develop our predictive model. This was complemented with
the CRONICAS Cohort Study [19], whose baseline and
longitudinal information was used to validate the risk score.
The ENINBSC is a national population-based survey
carried out in Peru between August 2004 and April 2005,
designed to estimate the prevalence of hypertension, type
2 diabetes mellitus, and other risk factors for noncom-
municable diseases at the national and regional level [18].
Potential participants were those aged ≥20 years, habitual
residents in the study area, and able to provide consent for
their participation in the study. Pregnant women and those
currently breastfeeding were excluded from the study. As
per design, the ENINBSC sample was stratified according to
Peru’s five major regions of the country: Lima, rest of the
Coast, urban Highlands, rural Highlands, and jungle. In each
stratum, cluster of blocks were chosen using single random
sampling techniques. Within each cluster, a random sample
of households and participants were selected.
The CRONICAS Cohort Study is an ongoing cardiopul-
monary project aimed to estimate the prevalence and inci-
dence of hypertension, diabetes mellitus, and obesity in
four different settings in Peru that differ in terms of their
urbanicity and altitude: Pampas de San Juan deMiraflores, in
the highly urbanized Lima, Puno in the altitude (3,825meters
above the sea level) contributing with rural and urban areas,
and Tumbes, a semiurban area in the northern coast of Peru
[19]. The study started in September 2010 and a follow-up
visit was completed in March 2014. A sex- and age-stratified
sample was selected at random for each of the settings and all
participants aged ≥35 years, full time residents in the study
area, and able to consent, were enrolled. Follow-up data used
for this analysis was collected, on average, at 30 months after
baseline.
2.2. Study Procedures. The procedures of the ENINBSC have
been described previously [18]. Briefly, after consent, two
different visits were scheduled.The first one lasted on average
40 minutes and was carried out to apply a face-to-face
questionnaire regarding data about household character-
istics, demographics, lifestyles behaviors, risk factors, and
blood pressure measurements. The second visit lasted 30
minutes on average and was planned to have an appropriate
period of fasting for blood sampling for glucose, total choles-
terol, HDL-cholesterol, and the remaining anthropometric
measures (height, weight, and waist circumference) using
standard procedures.
Similarly, the procedures of the CRONICAS study
has been published elsewhere [19]. In brief, participants
responded to a face-to-face questionnaire applied by trained
community health workers. Data collected comprised risk
factors for cardiovascular disease based on amodified version
of the WHO STEP approach questionnaire for surveillance
of noncommunicable disease [20]. A period of 8 to 12 hours
of fasting was required for blood sampling to collect fast-
ing glucose, total cholesterol, and HDL-cholesterol. Height,
weight, and waist circumference were also assessed, and
blood pressure was measured in triplicate after five minutes
of resting using an automatic monitor (OMRON HEM-780)
previously validated in adult’s population [21].
2.3. Variable Definitions. In both studies, diabetes was
defined as any of the following conditions: fasting glucose
≥7.0mmol/L (≥126mg/dL) and/or self-report of physician
diagnosis. Fasting glucose was assessed by an enzymatic
colorimetric method (glucose oxidase GOD-PAP) in both
studies. After excluding individuals without known diabetes,
undiagnosed diabetes was also estimated to develop and
validate the risk score [22].
Variables included in the analyses were built to guarantee
similarities between both studies: sex; age (<55 and ≥55
years); education (in years); self-reported smoking (current
versus never/former smoker); alcohol use (user versus never
user); self-reported diabetes in first-degree relatives (partici-
pant’s parents and/or siblings); and levels of physical activity
(low versus moderate/high levels, based on the transport-
related domain of the IPAQ). Anthropometricmeasurements
included in the analysis were body mass index ((BMI), <25,
25–29.9, and ≥30Kg/m2), waist circumference (<90, 90–
99.9, and ≥100 cm), waist-to-height ratio (<0.50, 0.50–0.59,
0.60–0.69, and ≥0.70) [23], and hypertension (measured or
previously diagnosed) [24].
2.4. Statistical Analysis. A total of 4,206 participants were
enrolled in the ENINBSC, but only 2,472 were included in
this analysis. Reasons for exclusion were 1,524 because of age
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<35 years to make both databases comparable, 129 because
of no data about fasting plasma glucose levels being available,
and 81 because of known diagnosis of diabetes. In the CRON-
ICAS study, 3,601 participants were enrolled at baseline but
only 2,948 records were analyzed as 465 had no data about
glucose levels, and 188 were excluded because of previous
diagnosis of diabetes. In addition, only data from 2,577 par-
ticipants was used in the longitudinal assessment of the risk
score (comparison of baseline characteristics among those
included and excluded from longitudinal analysis is shown
inOnline Supplement: E-Table 1; see SupplementaryMaterial
available online at http://dx.doi.org/10.1155/2016/8790235).
Initially, population characteristics of both studies were
tabulated using proportions in the case of categorical vari-
ables andmeans and standard deviation (SD) with numerical
variables. Then, the prevalence and 95% confidence intervals
(95% CI) of total diabetes and undiagnosed diabetes were
estimated in each study. After that, all cases of knowndiabetes
were excluded from subsequent analyses.
The risk score was derived from data of the ENINBSC
survey taking into account the multistage sampling strategy
of the study. Each potential risk factor (i.e., sex, age, family
history of diabetes, etc.) was assessed in bivariate models
using logistic regression and undiagnosed diabetes as the
dependent variable. Then, risk factors with a 𝑝 value <0.10
in the bivariate analysis were included in a multiple logistic
regression model using stepwise backward elimination with
a significance level of 5%.The Hosmer-Lemeshow goodness-
of-fit test was used to assess howwell the predicted prevalence
matched the observed prevalence of undiagnosed diabetes
(i.e., 𝑝 values over 0.20 indicate that model fits well) [25].
As we sought for an easily applicable and implementable
algorithm, the risk factors in the final model were each
assigned a weighted score by rounding up all regression
coefficients in the final model to the nearest integer as in a
previous report [26].
For the evaluation of the risk score, the area under the
receiver operating characteristic (ROC) curve, sensitivity,
specificity, and positive and negative predictive values (PPV
and NPV) were calculated. The optimal cut-point was deter-
mined using the Youden index, a single statistic that captures
the performance of a diagnostic test (i.e., sensitivity + speci-
ficity − 1) [27]. As one of the main aims of a nonlaboratory
risk score is to identify people who warrant having a blood
test (i.e., fasting glucose, glycated haemoglobin, etc.), the cut-
point with the highest sensitivity was also estimated and
described.
We assessed the performance of our score using bootstrap
techniques as well as carrying out an external validation
using the CRONICAS Cohort Study. Bootstrapping was
utilized to estimate confidence intervals for the AUC in our
study population. A total of 1,000 random samples with
replacement were taken from the development database.
The resulting 1,000 prediction models were then assessed to
estimate the bootstrap AUC using the bias-corrected version
of the confidence intervals [28]. In addition, using baseline
data from the CRONICASCohort Study, validationmeasures
(AUC, sensitivity, specificity, predictive values, and likelihood
ratios) were estimated.
To evaluate the performance of our algorithm, the Peru-
vian risk score was compared to previously published models
for undiagnosed diabetes including the Brazilian risk score
[16], the Qingdao score [10], the Indian risk score [11], the
Kuwaiti risk score [29], the patient self-assessment score
[26], and the Rotterdam risk score [7] using the c-statistic.
Finally, using the follow-up data of the CRONICAS Cohort
Study, the risk score was also evaluated to detect incident
cases of T2DM by excluding those with diabetes diagnosis
at baseline. Analyses were performed using STATA 13.0
(StataCorp, College Station, TX, USA).
2.5. Ethical Issues. The protocol and informed consent forms
of the ENINBSC study were reviewed and approved by
the Instituto Nacional de Salud and the Centro Nacional de
Alimentacio´n y Nutricio´n, both part of the Ministry of Health
in Lima, Peru. In the case of the CRONICAS Cohort Study,
protocol and consent forms were reviewed and approved
by the institutional review boards of the Universidad Peru-
ana Cayetano Heredia and the NGO Asociacio´n Bene´fica
PRISMA in Lima, Peru, and the Johns Hopkins University in
Baltimore, USA.
3. Results
The characteristics of participants in both studies are detailed
in Table 1. Overall, participants from the CRONICAS study
were 5 years older, reported consuming lower levels of
alcohol, and were less physically active than those from the
ENINBSC survey.
3.1. Prevalence of Diabetes and Undiagnosed Diabetes. The
overall prevalence of diabetes was 5.1% (129/2538; 95% CI:
4.2%–5.9%) in the ENINBSC survey and 8.7% (272/3135;
95% CI: 7.7%–9.7%) in the CRONICAS Cohort Study’s
baseline. After excluding those with known diabetes, undi-
agnosed diabetes was present in 2.0% (48/2457; 95%
CI: 1.4%–2.5%) in the ENINBSC survey and in 2.9%
(85/2948; 95% CI: 2.3%–3.5%) in the CRONICAS Cohort
Study.
3.2. Development of the Risk Score. After stepwise backward
logistic regression, age, diabetes in first-degree relatives,
and waist circumference were independently associated with
undiagnosed diabetes (Table 2). The Hosmer-Lemeshow test
showed that the final model fitted relatively well (𝑝 = 0.21).
The Peruvian diabetes risk score was constructed based on
the coefficients of that final regression model. The score gave
an AUC of 0.73 (95% CI: 0.65–0.78), and the optimal cut-
point for undiagnosed diabetes using the Youden index was
≥2 (Figure 1).With this cut-point, about 34.8% of participants
were categorized as at high risk of diabetes: sensitivity 69.6%,
specificity 65.8%, and PPV and NPV of 3.9% and 99.1%,
respectively.With a cut-point ≥1, 69.8% of participants would
be at high risk of diabetes with improved sensitivity (93.5%)
but lower specificity (30.6%). Table 3 shows the performance
of the risk score for detecting undiagnosed diabetes at
different cut-points.
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Table 1: Sociodemographic characteristics of participants without history of type 2 diabetes in the two involved studies.
ENINBSC study CRONICAS study
(𝑛 = 2,472) (𝑛 = 2,945)
Demographic variables
Sex (% females) 1,209 (48.9%) 1,500 (50.9%)
Age (mean (SD)) 50.5 (12.1) 55.3 (12.7)
Education in years (mean (SD)) 7.8 (4.9) 8.0 (4.9)
Behavioural variables
Current smoking (%) 391 (15.9%) 369 (11.5%)
Alcohol use (%) 2,323 (94.1%) 1,600 (54.3%)
Family history of diabetes (%) 268 (11.2%) 351 (11.9%)
Physical activity (% low level) 606 (24.5%) 938 (31.9%)
Anthropometric measures
Body mass index (mean (SD)) 25.7 (4.5) 27.6 (4.6)
Waist circumference (mean (SD)) 91.0 (11.4) 91.5 (11.0)
Waist-to-height ratio (mean (SD)) 0.58 (0.08) 0.59 (0.07)
Systolic blood pressure (mean (SD)) 114.5 (18.5) 117.2 (18.9)
Diastolic blood pressure (mean (SD)) 71.1 (11.9) 73.4 (11.1)
Hypertension (%) 579 (23.8%) 705 (24.0%)
Total cholesterol (mean (SD)) 174.2 (36.9) 199.7 (39.6)
HDL-cholesterol (mean (SD)) 43.5 (5.3) 41.7 (11.5)
SD: standard deviation and HDL: high-density lipoprotein.
Results may not add due to missing values.
Table 2: Risk factors and beta coefficients for undiagnosed diabetes: final regression model using CENAN database (𝑛 = 2,367).
Bivariate model Final model∗ Score
Coefficient (SE) OR (95% CI) Coefficient (SE) OR (95% CI)
Sex
Male (versus female) −0.39 (0.30) 0.68 (0.38–1.21)
Age
≥55 (versus <55 years) 0.72 (0.29) 2.05 (1.16–3.64) 0.61 (0.18) 1.85 (1.30–2.63) 1 (versus 0)
Current smoking
Current (versus never/former smoker) −1.06 (0.60) 0.34 (0.11–1.12)
Alcohol user
User (versus never user) 0.38 (0.74) 1.46 (0.34–6.27)
Diabetes in relatives
Yes (versus no) 1.06 (0.34) 2.90 (1.48–5.66) 0.85 (0.42) 2.34 (1.04–5.31) 1 (versus 0)
Physical activity
Low (versus moderate/high levels) 0.80 (0.30) 2.24 (1.25–4.01)
Body mass index
Overweight (versus normal) 0.07 (0.35) 1.07 (0.54–2.13)
Obese (versus normal) 0.80 (0.36) 2.23 (1.11–4.49)
Waist circumference
90.0 to <99.9 cm (versus <90 cm) 0.66 (0.38) 1.93 (0.91–4.10) 0.74 (0.33) 2.09 (1.09–4.02) 1 (versus 0)
100+ cm (versus <90 cm) 1.41 (0.37) 4.10 (1.99–8.44) 1.40 (0.23) 4.07 (2.60–6.40) 2 (versus 0)
Waist-to-height ratio
0.50–0.59 (versus <0.50) 0.34 (0.63) 1.41 (0.41–4.86)
0.60–0.69 (versus <0.50) 1.09 (0.62) 2.97 (0.88–10.0)
0.70+ (versus <0.50) 1.58 (0.68) 4.84 (1.27–18.5)
Hypertension
Yes (versus no) 0.52 (0.31) 1.68 (0.91–3.09)
∗Themodel was created using backward elimination from the initial full model until we reached a final model with statistically significant covariates.
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Table 3: Performance of different cut-points for detecting undiagnosed type 2 diabetes in the development database.
Total score At high risk∗ Sensitivity Specificity PPV NPV Correctly classified LR+ LR−
≥1 69.8% 93.5% 30.6% 2.6% 99.6% 31.8% 1.34 0.21
≥2 34.9% 69.6% 65.8% 3.9% 99.1% 65.9% 2.04 0.46
≥3 11.0% 30.4% 89.4% 5.4% 98.5% 88.3% 2.87 0.78
≥4 1.3% 2.2% 98.7% 3.2% 98.1% 96.8% 1.68 0.99
PPV: positive predictive value; NPV: negative predictive value; LR+: positive likelihood ratio; LR−: negative likelihood ratio.
∗Those at high risk are the proportion of participants over the total score.
Table 4: Performance of different diabetes risk scores compared to Peruvian diabetes risk score using the CRONICAS study (validation
sample).
Method (proposed cutoff) # of variables AUC Sensitivity Specificity PPV NPV LR+ LR−
Brazilian risk score (≥18) 3 0.65 66.7% 61.9% 4.9% 98.4% 1.75 0.54
Qingdao risk score (≥17 and ≥14)∗ 4 0.58 83.3% 33.3% 3.6% 98.5% 1.25 0.50
Indian risk score (≥21) 5 0.54 94.0% 15.5% 3.1% 98.9% 1.11 0.39
Kuwaiti risk score (≥32) 4 0.62 45.2% 78.4% 5.8% 98.0% 2.09 0.70
Patient self-assessment score (≥5) 6 0.64 61.4% 66.8% 5.1% 98.3% 1.85 0.58
Rotterdam risk score (≥36) 6 0.55 94.0% 16.8% 3.2% 99.0% 1.13 0.35
Peruvian risk score (≥2) 3 0.68 70.2% 58.9% 4.8% 98.5% 1.71 0.51
AUC: area under the ROC curve; PPV: positive predictive value; NPV: negative predictive value; LR+: positive likelihood ratio; LR−: negative likelihood ratio.
∗Different cutoffs for males (≥17) and females (≥14).
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Figure 1: Receiver operating characteristic (ROC) curve of the risk
score in predicting undiagnosed type 2 diabetes in the development
database. The area under the ROC curve was 0.73 (95% CI: 0.65–
0.78) for the risk score.
3.3. Cross-Sectional Validation of the Risk Score. When boot-
strap was used, the performance of our risk score was similar
to the obtained in the development model (AUC = 0.72;
95% CI: 0.65–0.78). In addition, when the risk score was
evaluated by applying the score to the CRONICAS Cohort
Study’s population, the AUC for undiagnosed diabetes was
0.68 (95% CI: 0.62–0.73). At the suggested cut-point of ≥2,
42% would be categorized as undiagnosed diabetes with
sensitivity, specificity, PPV, and NPV of 70.2%, 58.9%, 4.8%,
and 98.5%, respectively (Table 4). On the other hand, with
a cut-point ≥1, 80% would be categorized as undiagnosed
diabetes with sensitivity, specificity, PPV, and NPV of 94.0%,
20.0%, 3.3%, and 99.1%, respectively.
When previous published algorithms for undiagnosed
diabetes were applied to the CRONICAS Cohort Study, the
performance of the Rotterdam score (𝑝 < 0.001), Indian
score (𝑝 < 0.001), and Qingdao score (𝑝 < 0.01) was poorer
than our score; however, our algorithm performed similar to
the other assessed models, such as the Brazilian risk score
(𝑝 = 0.93), the Kuwaiti score (𝑝 = 0.26), and the patient self-
assessment score (𝑝 = 0.74), but having only three variables.
3.4. Longitudinal Assessment of the Risk Score. The per-
formance of this risk score was also assessed to predict
incident cases of diabetes using the longitudinal data from
the CRONICASCohort Study. One hundred twenty-one new
cases of diabetes were found accounting for 6,207 person-
years at risk, with an overall incidence of 1.95 (95% CI: 1.63–
2.33) cases per 100 person-years of risk.The AUC of the score
was 0.66 (95% CI: 0.61–0.71). With a cut-point ≥2, 42.5% of
participants were categorized as at high risk of developing
diabetes: sensitivity, specificity, PPV, and NPV were 69.4%,
58.9%, 7.8%, and 97.4%, whereas, for a cut-point ≥1, the
respective values were 79.9%, 91.9%, 20.7%, 5.5%, and 98.1%.
4. Discussion
4.1. Main Findings. Using a national population-based sur-
vey, a simple nonblood based risk score based on age, history
of diabetes in first-degree relatives, and waist circumference
was built and shown to perform moderately in detecting
undiagnosed diabetes when externally validated. Moreover,
the performance of the score was almost similar for detecting
incident cases of diabetes in the Peruvian population.
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4.2. Comparison with Other Risk Scores. A relatively recent
systematic literature search found 23 different blood-free
prevalent diabetes risk scores: ten from Europe, nine for
Asian populations, two from the United States, and two
from Middle East [30]. In addition, and not included in the
aforementioned review, only one risk score was developed
in Latin America using Brazilian urban population [16]. The
same systematic review reported that AUC for these predic-
tive models was greater in the development studies (range:
0.65 to 0.88) than in the validation studies (range: 0.63 to
0.80) [30], similar to our findings. Another systematic review
found that several noninvasive algorithms were created using
variables such as age, gender, waist circumference and/or
BMI, and family history of diabetes in the final model [31].
As impracticality due to use of the algorithms was a common
barrier to the uptake of risk scores by healthcare staff and
individuals [32], our model, created with three of these more
common variables, reached a moderate-to-high sensitivity
depending on the used cut-point. Moreover, two of these
variables are easily evaluable during medical appointment or
through individual’s self-assessment, and only a measuring
tape and no calculations are required to be implemented in
clinical practice or at the population level.
From a cross-sectional point of view, with a cut-point
≥2, from 1000 participants assessed by the Peruvian diabetes
risk score, a total of 420 would be classified as undiagnosed
diabetes with the detection of 20 cases and only 6 will be
missing. On the other hand, with a cut-point ≥1, from 1000
screened individuals, a total of 804 would be categorized
as having undiagnosed diabetes with the detection of 27
cases and only 7 will be missing. Thus, the reduction of
the cut-point of the risk score would increase sensitivity but
reducing the specificity and imposing the need of performing
a confirmatory test (i.e., fasting glucose) to almost the double
of individuals, with the benefit of having only 7 more people
diagnosed.
Longitudinally, the same risk score would detect an
important number of participants at risk of developing
diabetes: 43% of screened individuals would be classified
at high risk of diabetes, and of them, 8% would develop
diabetes in the next 2.5 years. According to a previous study
[33], 17 reports described a noninvasive model to predict the
development of diabetes and included a median of six risk
predictors, ranging from 2 to 11 [34]. Although our score
did not perform as good as other well-known longitudinal
models in the literature such as the FINDRISC or the ARIC
scores [35, 36], it only included three variables and was
built using cross-sectional information. In addition, some
variables used in the aforementioned studies are difficult to
standardize within a country as Peru, that is, food portions,
physical activity, or sedentarism, limiting therefore its use on
a wider scale and in a simple pragmatic fashion.
Our algorithm performed better than the Rotterdam, the
Indian, and the Qingdao risk scores in our population, which
highlights the need of calibration and/or development of a
specific score for different ethnic groups before its adoption.
As there are ethnic differences in risk factors for diabetes
and Peru is considered a multiethnic country, it is necessary
to create specific scores or recalibrate existing algorithms
before applying in specific contexts. In addition, with only
three variables included, the performance of our predictive
model was similar to the other assessed scores included in
the analyses. Taken together, the score developed has the
potential to augment, in a pragmatic manner, initial rapid
screening for diabetes, especially at various nonspecialized
primary healthcare services.
Our findings also demonstrate that approximately 35% of
cases of T2DM (39% in the ENINBSC survey and 33% in the
baseline of the CRONICAS Cohort Study) are not aware of
their disease. Results are similar to those reported in previous
studies in our context [37] and in similar settings in Latin
America [38].
4.3. Public Health Relevance and Implications. As the devel-
oped risk score is simple, it does not require a blood test or
laboratory services, and it might be easily implemented in
clinical practice.Moreover, because our score asks for general
information in the form of age and diabetes in first-degree
relatives and is complemented by a simple anthropometric
measure of waist, there is potential for the score to be self-
administered.
According to our results, any patient aged 55 years and
above and having at least one first-degree relative with T2DM
has greater probability of having undiagnosed diabetes but
also is at risk of developing diabetes in the future. In addition,
a greater central obesity, that is, 100 cm ormore, independent
of the other terms of the score is alone a good predictor of
diabetes as reported in previous studies [23]. Our algorithm
included waist circumference instead of body mass index as
other risk scores, providing a better indicator of accumulation
of visceral fat and metabolic dysfunction in our context [39].
Recently, the Peruvian Ministry of Health has published
the Guide of Clinical Practice for Diagnosis, Treatment
and Control of Diabetes Mellitus in Primary Care [40]
and only recommends screening in general population with
plasma glucose among adults between 40 and 70 years with
obesity or overweight as suggested by the American Diabetes
Association [6]. As in other LMIC, plasma glucose is not
always available in primary care, especially in semiurban and
rural areas; therefore, a major challenge to be overcome in
many countries is the implementation of a simple, fast, and
laboratory-free based screening method. Moreover, within
the Peruvian context, no risk score has been proposed as part
of the aforementioned guide. Thus, our algorithm might fill
a gap to facilitate further specialized assessment of high risk
individuals for diabetes, an approach that may be of utility to
various other countries facing similar challenges.
4.4. Strengths and Limitations. The strengths of this study
include the use of a national population-based survey, includ-
ing urban and rural areas across major geographical regions,
to develop the Peruvian diabetes risk score, as well as its
validation using bootstrap but also an independent longi-
tudinal cohort study. Additionally, it is only based on three
variables ensuring its simplicity to be used and implemented.
However, the study has also some limitations. First, we
have utilized fasting plasma glucose as the gold standard
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for diagnosing diabetes instead of an oral glucose tolerance
test (OGTT). Although the OGTT is more sensitive and
specific than the fasting plasma glucose, more cases would
have been detected with the overload of glucose; it is rarely
performed as part of the routine clinical practice. Second, the
CRONICAS Cohort Study did not include information from
the Amazon rainforest as did the ENINBSC survey. When
a sensitivity analysis was performed excluding individuals
from the jungle from ENINBSC data, results were similar
to those presented in this manuscript (data not shown).
In addition, the score was created using a national survey
to be applicable to the entire Peruvian population. Third,
some variables were not assessed in our logistic regression
model such as dietary intake or history of gestational diabetes
as such data was not available. As a result, some caution
should be made when our algorithm is compared to other
risk scores. Fourth, our model is based on the idea of risk
stratification instead of individualisation [41]; for instance,
variables were categorized instead of being preserved as
numerical. Nevertheless, the performance of our score did
not change when age and waist circumference were treated
as numerical variables (data not shown). Moreover, our idea
was to develop a simple and easily applicable score instead
of a complex algorithm for predicting undiagnosed and
incident diabetes. Finally, as other diabetes risk scores, the
model warrants further scrutiny before it can be used in other
populations.
5. Conclusions
ThePeruvian diabetes risk score, built using age, self-reported
diabetes in first-degree relatives, and waist circumference,
proves to be a simple pragmatic screening tool for undiag-
nosed and incident cases of diabetes in Peru.This experience
in generating such simple, easy-to-use approaches for the
identification of T2DM can serve to inform other similar
LMIC efforts who are on early stages of diabetes prevention.
This tool, due to its simplicity, can facilitate various initiatives
oriented to introduce and scale up early preventative and
management strategies on a wider scale.
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